Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Q4 2024 Management View CEO Pablo Legorreta highlighted strong 2024 performance, reporting $2.8 billion in portfolio receipts, at the high end of guidance and reflecting 13% growth in Royalty Receipts ...

(NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong fourth quarter results due to solid operational performance driven by top ...

Gujarat Titans are set to experience an ownership shakeup, with Torrent Group acquiring 66 per cent of the franchise.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Walter Kimble has opened his own Seniors Helping Seniors franchise in Philadelphia with ... childhood vaccines during a 35-year career in the pharmaceutical industry, Walter Kimble has turned ...

Royalty Pharma Plc provides drug development services ... Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

Alliance Pharma said that expected revenue fell, dragged down by consumer healthcare, and stuck to its guidance for the year.

In a massive development regarding the Gujarat Titans franchise, their owners CVC Capital are reportedly set to sell 67% ...